CA2227421A1 - Use of ipriflavone to reduce the number of cd8+ cells - Google Patents

Use of ipriflavone to reduce the number of cd8+ cells Download PDF

Info

Publication number
CA2227421A1
CA2227421A1 CA002227421A CA2227421A CA2227421A1 CA 2227421 A1 CA2227421 A1 CA 2227421A1 CA 002227421 A CA002227421 A CA 002227421A CA 2227421 A CA2227421 A CA 2227421A CA 2227421 A1 CA2227421 A1 CA 2227421A1
Authority
CA
Canada
Prior art keywords
cells
decrease
isopropoxyisoflavone
ipriflavone
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002227421A
Other languages
English (en)
French (fr)
Inventor
Gyorgy Varai
Attila Tar
Attila B.Kovacs
Terezia Kerepesi
Peter Aranyi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chinoin Private Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2227421A1 publication Critical patent/CA2227421A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
CA002227421A 1995-07-21 1996-07-16 Use of ipriflavone to reduce the number of cd8+ cells Abandoned CA2227421A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HUP9502198 1995-07-21
HU9502198A HU9502198D0 (en) 1995-07-21 1995-07-21 Novel indication

Publications (1)

Publication Number Publication Date
CA2227421A1 true CA2227421A1 (en) 1997-02-06

Family

ID=10987063

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002227421A Abandoned CA2227421A1 (en) 1995-07-21 1996-07-16 Use of ipriflavone to reduce the number of cd8+ cells

Country Status (22)

Country Link
EP (1) EP0841915A1 (cs)
JP (1) JP2001503371A (cs)
KR (1) KR19990028933A (cs)
CN (1) CN1191483A (cs)
AR (1) AR002905A1 (cs)
AU (1) AU6367096A (cs)
BG (1) BG102182A (cs)
BR (1) BR9610187A (cs)
CA (1) CA2227421A1 (cs)
CZ (1) CZ2798A3 (cs)
EA (1) EA199800146A1 (cs)
EE (1) EE9800020A (cs)
HR (1) HRP960345A2 (cs)
HU (1) HU9502198D0 (cs)
IL (1) IL122751A0 (cs)
MX (1) MX9800603A (cs)
NO (1) NO980127D0 (cs)
PL (1) PL324460A1 (cs)
SK (1) SK3298A3 (cs)
WO (1) WO1997003664A1 (cs)
YU (1) YU42796A (cs)
ZA (1) ZA966079B (cs)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1241079B (it) * 1990-03-23 1993-12-29 Chiesi Farma Spa Composizioni farmaceutiche contenenti ipriflavone,procedimento per la loro preparazione e relativo impiego terapeutico
HU212932B (en) * 1993-08-02 1996-12-30 Chinoin Gyogyszer Es Vegyeszet Parmaceutical composition containing ipriflavone, hydroxyapatit and tricalciumphosphate for treating lack of bones and process for producing the composition

Also Published As

Publication number Publication date
MX9800603A (es) 1998-04-30
SK3298A3 (en) 1998-07-08
AU6367096A (en) 1997-02-18
CZ2798A3 (cs) 1998-06-17
NO980127L (no) 1998-01-12
WO1997003664A1 (en) 1997-02-06
EE9800020A (et) 1998-08-17
HU9502198D0 (en) 1995-09-28
AR002905A1 (es) 1998-04-29
BG102182A (bg) 1998-08-31
EP0841915A1 (en) 1998-05-20
PL324460A1 (en) 1998-05-25
CN1191483A (zh) 1998-08-26
IL122751A0 (en) 1998-08-16
HRP960345A2 (en) 1998-02-28
JP2001503371A (ja) 2001-03-13
YU42796A (sh) 1999-03-04
ZA966079B (en) 1998-01-19
NO980127D0 (no) 1998-01-12
BR9610187A (pt) 1998-07-28
KR19990028933A (ko) 1999-04-15
WO1997003664A8 (en) 1999-08-05
EA199800146A1 (ru) 1998-08-27

Similar Documents

Publication Publication Date Title
DE60225914T2 (de) Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4-mutationsmolekülen
DE69837324T2 (de) Behandlung der multiplen sklerose durch einnahme von copolymer-1
JP2003510353A (ja) 自己免疫疾患、慢性ウイルス性および細胞内細菌性感染症の治療のためのアスタキサンチン等のキサントフイルの使用
US10350231B2 (en) Use of cladribine for treating autoimmune inflammatory disease
US20180185300A1 (en) Cannabidiol for the prevention and treatment of graft-versus-host disease
US20250302858A1 (en) Use of cladribine for treating autoimmune neuromuscular disease
AU615745B2 (en) Method of effecting immunosuppression
Ryffel et al. Immunosuppressive effect of cyclosporin A in two lymphocyte transfer models in rats: comparison of in vivo and in vitro treatment
AU641002B2 (en) Method of treatment of retrovirus infections
CA2227421A1 (en) Use of ipriflavone to reduce the number of cd8+ cells
MXPA98000603A (en) Use of ipriflavona to reduce the number of cells c
US20150374667A1 (en) Compositions And Method For Treatment Of Ischemic Neuronal Reperfusion Injury
JP3010258B2 (ja) 抗ｈｉｖ剤
Strober ‘Managing’the Immune System With Total Lymphoid Irradiation
JP2928608B2 (ja) インスリン依存型糖尿病予防または治療剤
KR100329835B1 (ko) 베체트병 치료에 사용되는 수산화 알루미늄 애쥬번트에흡착된 오발부민을 포함하는 티에이치2 애쥬번트
HK40031112B (en) Use of cladribine for treating autoimmune neuromuscular disease
KR20240115760A (ko) 가세리를 포함하는 면역조절 유도 조성물
CN110354168A (zh) 一种治疗肾透明细胞癌的药物组合物及其制备方法
Feinberg Update on treatment of CMV retinitis
JPH107556A (ja) 細胞接着抑制剤
JPH04154723A (ja) 白血球減少症の予防・治療剤
MXPA99006457A (en) Treatment of multiple sclerosisthrough ingestion or inhalation of copolymer-1
JPS58208229A (ja) 抗腫瘍剤

Legal Events

Date Code Title Description
FZDE Discontinued